OBJECTIVE: To identify the genetic cause of an autosomal recessive demyelinating Charcot-Marie-Tooth disease type 4B (CMT4B) family. METHODS: We enrolled 14 members of a Korean family in which 3 individuals had demyelinating CMT4B phenotype and obtained distal sural nerve biopsies from all affected participants. We conducted exome sequencing on 6 samples (3 affected and 3 unaffected individuals). RESULTS: One pair of heterozygous missense mutations in the SET binding factor 1 (SBF1) gene (22q13.33), also called MTMR5, was identified as the underlying cause of the CMT4B family illness. Clinical phenotypes of affected study participants with CMT4B were similar, to some extent, to patients with CMT4B1 and CMT4B2. We found a similar loss of large myelinated fibers and focally folded myelin sheaths in our patients, but the actual number of myelinated fibers was different from CMT4B1 and CMT4B2. CONCLUSIONS: We suggest that the compound heterozygous mutations in SBF1 are the underlying causes of a novel CMT4B subtype, designated as CMT4B3. We believe that this study will lead to mechanistic studies to discover the function of SBF1 and to the development of molecular diagnostics for CMT disease.
OBJECTIVE: To identify the genetic cause of an autosomal recessive demyelinating Charcot-Marie-Tooth disease type 4B (CMT4B) family. METHODS: We enrolled 14 members of a Korean family in which 3 individuals had demyelinating CMT4B phenotype and obtained distal sural nerve biopsies from all affected participants. We conducted exome sequencing on 6 samples (3 affected and 3 unaffected individuals). RESULTS: One pair of heterozygous missense mutations in the SET binding factor 1 (SBF1) gene (22q13.33), also called MTMR5, was identified as the underlying cause of the CMT4B family illness. Clinical phenotypes of affected study participants with CMT4B were similar, to some extent, to patients with CMT4B1 and CMT4B2. We found a similar loss of large myelinated fibers and focally folded myelin sheaths in our patients, but the actual number of myelinated fibers was different from CMT4B1 and CMT4B2. CONCLUSIONS: We suggest that the compound heterozygous mutations in SBF1 are the underlying causes of a novel CMT4B subtype, designated as CMT4B3. We believe that this study will lead to mechanistic studies to discover the function of SBF1 and to the development of molecular diagnostics for CMT disease.
Authors: Dana Gabrikova; Martin Mistrik; Jarmila Bernasovska; Alexandra Bozikova; Regina Behulova; Iveta Tothova; Sona Macekova Journal: J Appl Genet Date: 2013-08-31 Impact factor: 3.240
Authors: Anne M Logan; Anna E Mammel; Danielle C Robinson; Andrea L Chin; Alec F Condon; Fred L Robinson Journal: Glia Date: 2017-06-15 Impact factor: 7.452
Authors: Andreea Manole; Alejandro Horga; Josep Gamez; Nuria Raguer; Maria Salvado; Beatriz San Millán; Carmen Navarro; Alan Pittmann; Mary M Reilly; Henry Houlden Journal: Neurogenetics Date: 2016-12-22 Impact factor: 2.660
Authors: Tatiana Tiago; Barbara Hummel; Federica F Morelli; Valentina Basile; Jonathan Vinet; Veronica Galli; Laura Mediani; Francesco Antoniani; Silvia Pomella; Matteo Cassandri; Maria Giovanna Garone; Beatrice Silvestri; Marco Cimino; Giovanna Cenacchi; Roberta Costa; Vincent Mouly; Ina Poser; Esti Yeger-Lotem; Alessandro Rosa; Simon Alberti; Rossella Rota; Anat Ben-Zvi; Ritwick Sawarkar; Serena Carra Journal: Cell Death Dis Date: 2021-05-06 Impact factor: 8.469